April 2, 2019

CYPRE PRESENTS DATA AT AACR IN COLLABORATION WITH GENENTECH DEMONSTRATING PROPRIETARY IMMUNO-ONCOLOGY PLATFORM FOR ASSAYING CRITICAL PHENOTYPES.

 

March 17, 2019

CYPRE TO FOCUS EFFORTS ON ITS IMMUNO-ONCOLOGY PLATFORM AND CO-DEVELOPMENT COLLABORATIONS.

 

Feb 2, 2019

CYPRE AND MOLECULAR DEVICES PRESENT DATA AT SLAS CONFERENCE RELATED TO 3D IMAGE ANALYSIS USING 3D PLATFORM AND HIGH CONTENT IMAGING.

 

Jan 15, 2019

PEER-REVIEWED MANUSCRIPT ACCEPTED FOR PUBLICATION IN MOLECULAR CANCER THERAPEUTICS DEMONSTRATING GLIOBLASTOMA PATIENT AND RENAL CELL CARCINOMA PDX TUMOR TESTING EX VIVO WITH STANDARD OF CARE AND EXPERIMENTAL SMALL MOLECULES.

 

Sept 25, 2018

GENENTECH PRESENTS DATA AT LRIG CONFERENCE FROM COLLABORATION WITH CYPRE ON IMMUNO-ONCOLOGY PLATFORM.

 

Summer 2017

CYPRE SIGNS COLLABORATION DEALS WITH TWO PHARMACEUTICALS AROUND IMMUNO-ONCOLOGY PLATFORM.

 

February 2017

CYPRE RECEIVES SEED FUNDING FROM HEMI VENTURES AND ANGELS.

 

April 2016

CYPRE AND CEDARS SINAI SIGN COLLABORATION AGREEMENT TO TEST PATIENT TUMORS IN CYPRE 3D PLATFORM.

 

January 2016

CYPRE INC FOUNDED AND JOINS MBC BIOLABS (FORMERLY QB3@953), SAN FRANCISCO’S PREMIER BIOTECH INCUBATOR.